Lung cancer is still the leading cancer-related cause of death with a high incidence rate in the whole world. Treatment options -surgery, radiotherapy, and chemotherapy, depending on the stage of the disease. During the last decade, many molecular alterations were discovered that led to impressive changes in treatment. Personalized approaches, including part of the standard therapies. This article reviews current cancer patients.
Introduction
Lung cancer is the leading cause of cancer-related mortality in the whole world. It causes the highest Non-small cell lung cancer (NSCLC), which accounts for healthcare systems due to poor response rates, poor cancer was reported as the most common malignancy cases in men, and the seventh most common in females role of some mutations in the progression of the disease clinical importance in the recent years, and some expected, treatment for lung cancer has also changed.
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of importance for the current clinical practice in lung cancer treatment.
Discussion
and the small molecules that target certain genetic alterations were introduced into routine clinical practice. The paradigm for treatment and differentiation of the cell itself. Since the as retroviral oncogenes from the genome rat predominately found in adenocarcinomas frequently mutated gene in NSCLC, there is though with a low frequency that ranges from one mutations are divided into common (del exon mutations. Common mutations are considered to mutation frequency in NSCLC is considered survival rates, as compared to standard platinum- Toxicity is of huge importance in the treatment for lung cancer since therapy-related side effects are often a reason for therapy interruptions single nucleotide polymorphisms (SNPs) which could explain the differences in the response rates to cytotoxic therapy and therapy failure, suppressor gene of extreme importance for the cell cycle, plays the role of regulator of the for the normal function of the cell cycle prove its costs. Since research in oncology is expanding, the cost of the studies is of extreme importance. The recently used NGS method, as well as effective sequencing and easier data analysis, which is important for the rapidly developing genomics is associated with high-throughput sequencing technologies.
Conclusions
as a routine tool in clinical practice has led to survival rates, thus giving lung cancer patients with the advanced and metastatic disease a new oncologists still face the need of new targeted approaches to cover the increasing challenge of treatment resistance and related side effects, genetic discoveries, which have changed the part of diagnosing and treatment of patients with advanced NSCLC, some of them already a diagnostic routine in practice; many others technologies in diagnosing, treatment and prediction of outcome in clinical practice. 
